Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 32

Publication Record

Connections

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.
Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S
(2017) Nat Commun 8: 606
MeSH Terms: 4-1BB Ligand, Animals, Breast Neoplasms, Cell Line, Tumor, Cell Proliferation, Female, Humans, Immunotherapy, Lymphocytes, Tumor-Infiltrating, MAP Kinase Kinase 1, MAP Kinase Kinase 2, MAP Kinase Signaling System, Mammary Neoplasms, Animal, Mice, OX40 Ligand, Protein Kinase Inhibitors, Pyridones, Pyrimidinones, T-Lymphocyte Subsets, T-Lymphocytes, Triple Negative Breast Neoplasms
Added March 14, 2018
0 Communities
1 Members
0 Resources
21 MeSH Terms
Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Johnson AS, Crandall H, Dahlman K, Kelley MC
(2015) J Am Coll Surg 220: 581-93.e1
MeSH Terms: Administration, Oral, Adult, Aged, Biomarkers, Tumor, Biopsy, DNA Mutational Analysis, DNA, Neoplasm, Dose-Response Relationship, Drug, Drug Therapy, Combination, Feasibility Studies, Female, Follow-Up Studies, Humans, Imidazoles, MAP Kinase Kinase 1, Male, Melanoma, Middle Aged, Mitogen-Activated Protein Kinases, Mutation, Oximes, Preoperative Care, Prospective Studies, Proto-Oncogene Proteins B-raf, Pyridones, Pyrimidinones, Skin Neoplasms, Young Adult
Added February 16, 2016
0 Communities
1 Members
0 Resources
28 MeSH Terms
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M
(2015) Clin Cancer Res 21: 1935-43
MeSH Terms: Adenocarcinoma, Adenocarcinoma of Lung, Aged, Aged, 80 and over, Alleles, Cell Line, DNA Mutational Analysis, Exons, Female, Gene Frequency, Genotype, Humans, Lung Neoplasms, MAP Kinase Kinase 1, Male, Middle Aged, Models, Molecular, Mutation, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Protein Conformation, Smoking
Added September 10, 2020
0 Communities
1 Members
0 Resources
MeSH Terms
Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation.
Aldrovandi M, Hammond VJ, Podmore H, Hornshaw M, Clark SR, Marnett LJ, Slatter DA, Murphy RC, Collins PW, O'Donnell VB
(2013) J Lipid Res 54: 3085-97
MeSH Terms: Aspirin, Blood Platelets, Calcium, Cyclooxygenase 1, Cyclooxygenase Inhibitors, Dinoprostone, Dose-Response Relationship, Drug, Esterification, Feedback, Physiological, Humans, Intracellular Space, MAP Kinase Kinase 1, Phosphatidylethanolamines, Phospholipids, Platelet Activation, Prostaglandin D2, Prostaglandins, Protein Kinase C, Receptor, PAR-1, Thrombin, src-Family Kinases
Added March 7, 2014
0 Communities
1 Members
0 Resources
21 MeSH Terms
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A
(2013) J Clin Oncol 31: 1767-74
MeSH Terms: Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Apoptosis, Cell Cycle, Cell Proliferation, Disease Progression, Drug Resistance, Neoplasm, Female, GTP Phosphohydrolases, Humans, Immunohistochemistry, Indoles, MAP Kinase Kinase 1, MAP Kinase Signaling System, Male, Melanoma, Membrane Proteins, Middle Aged, Mitogen-Activated Protein Kinase Kinases, Point Mutation, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Sulfonamides, Tumor Cells, Cultured, Vemurafenib
Added March 5, 2014
0 Communities
2 Members
0 Resources
29 MeSH Terms
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD
(2013) J Clin Oncol 31: 482-9
MeSH Terms: Adult, Aged, Antineoplastic Agents, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Male, Melanoma, Middle Aged, Mutation, Neoplasm Staging, Proto-Oncogene Proteins B-raf, Pyridones, Pyrimidinones, Skin Neoplasms, Treatment Outcome
Added March 20, 2014
0 Communities
1 Members
0 Resources
19 MeSH Terms
Cadherin-11 regulates cell-cell tension necessary for calcific nodule formation by valvular myofibroblasts.
Hutcheson JD, Chen J, Sewell-Loftin MK, Ryzhova LM, Fisher CI, Su YR, Merryman WD
(2013) Arterioscler Thromb Vasc Biol 33: 114-20
MeSH Terms: Actins, Animals, Aortic Valve, Cadherins, Calcinosis, Cell Communication, Cells, Cultured, Female, Heart Valve Diseases, Humans, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Male, Middle Aged, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Morphogenesis, Myofibroblasts, Phosphorylation, Protein Kinase Inhibitors, RNA Interference, Signal Transduction, Stress, Mechanical, Swine, Transfection, Transforming Growth Factor beta1
Added December 10, 2013
0 Communities
2 Members
0 Resources
26 MeSH Terms
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W
(2012) Proc Natl Acad Sci U S A 109: E2127-33
MeSH Terms: Amino Acid Substitution, Cell Line, Tumor, Clinical Trials as Topic, Drug Resistance, Neoplasm, ErbB Receptors, Female, Humans, Lung Neoplasms, MAP Kinase Kinase 1, Male, Mutation, Missense, Protein Kinase Inhibitors, Proto-Oncogene Proteins, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins p21(ras), ras Proteins
Added September 3, 2013
0 Communities
2 Members
0 Resources
16 MeSH Terms
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS
(2012) Cancer Discov 2: 414-24
MeSH Terms: Adult, Aged, Antineoplastic Agents, Cell Line, Tumor, Drug Resistance, Neoplasm, Exons, Female, HEK293 Cells, Humans, Imidazoles, Indoles, MAP Kinase Kinase 1, Male, Melanoma, Middle Aged, Mutation, Oximes, Proto-Oncogene Proteins B-raf, Sulfonamides, Vemurafenib
Added March 20, 2014
0 Communities
2 Members
0 Resources
20 MeSH Terms
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS
(2012) Nat Commun 3: 724
MeSH Terms: Adult, Aged, Antineoplastic Agents, Base Sequence, Benzimidazoles, Cell Line, Cell Line, Tumor, DNA Copy Number Variations, Drug Resistance, Neoplasm, Exome, Extracellular Signal-Regulated MAP Kinases, Female, Gene Amplification, HEK293 Cells, Humans, Indoles, MAP Kinase Kinase 1, Male, Melanoma, Middle Aged, Proto-Oncogene Proteins B-raf, Sequence Analysis, DNA, Sulfonamides, Vemurafenib
Added March 20, 2014
0 Communities
2 Members
0 Resources
24 MeSH Terms